-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Peptide drugs are a new type of drug with high activity and low toxicity.
In recent years, they have become a hot spot in the research and development of global pharmaceutical companies, and are gradually applied to the research and development of new therapies in the fields of tumors, pain, and metabolic diseases
.
Compared with small molecule drugs, the number of peptide drugs that have been approved for marketing is relatively small, and the industry believes that the growth potential of this drug is huge
.
At present, Pfizer, Merck, Roche, Eli Lilly, Novartis, Sanofi, Bayer and other multinational pharmaceutical companies have increased their R&D investment in the field of peptide drug research, and actively deployed through mergers and acquisitions
.
In recent years, the effect of head companies has become prominent, including Lilly's dulaglutide, Novo Nordisk's semaglutide, and Takeda Pharmaceutical's leuprolide acetate, all of which are blockbuster varieties with annual sales of hundreds of millions of dollars
.
In China, with the rapid development of foreign peptide drug research and development and the rapid development of the peptide drug market, some local pharmaceutical companies have gradually joined the field, aiming at the blue ocean of the market
.
For example, Ambio Pharmaceuticals, Sino Biological, Nuotai Biological, Asymchem,
etc.
Recently, the deployment of peptide drugs by many pharmaceutical companies has also attracted the attention of the industry
.
For example, Yuekang Pharmaceutical told investors on the interactive platform on February 21 that the company's peptide drugs are currently in the preclinical research stage in China.
For the progress of the project, please pay attention to the follow-up project progress announcement and regular reports; January 28 In the research report, Nuotai Biological mentioned that the company currently has 4 peptide CDMO projects in the early stage in the process of cooperation promotion
.
If there are relevant major developments, the company will disclose it in relevant announcements and periodic reports in accordance with the requirements of the listing rules
.
In addition to the application in the field of medicine, the application of peptide drugs in other fields has also attracted the attention of investors
.
The secretary of the board of Hanyu Pharmaceutical recently replied to investors that the active ingredient polypeptide can be used in the development of drugs and skin care products
.
Among them, in terms of innovative peptide drugs, the future research and development directions include tumor/immune system, anti-virus, anti-infection, vaccine, central nervous system, metabolism and other emerging treatment and prevention fields
.
In terms of skin care products, Hanyu Original, a subsidiary of Hanyu Pharmaceutical, is mainly engaged in the wholesale and retail of peptide skin care products.
Online sales on e-commerce platforms
.
According to relevant statistics, the peptide drug market in 2020 has reached 28.
5 billion US dollars, and the market is developing rapidly.
The industry expects that the market value of peptide drugs will increase by 9% in the next five years
.
The growth space of the entire peptide drug market is huge
.
It is worth mentioning that in recent years, with the entry of a large number of domestic and foreign pharmaceutical companies, the competition on the track has become more intense
.
Statistics show that as of February 2021, there are about 80 approved peptide drugs in the world, and more than 400 peptide molecules are in preclinical research
.
It is foreseeable that the competition in this market will be more intense in the future, and companies with a preemptive layout and rich product lines are expected to benefit
.
The industry also pointed out that although the market prospect of peptide drugs is promising, the enterprises that deploy drugs will still face challenges such as production capacity resource constraints, imperfect process research and development capabilities, and single platform in the process of advancing drugs to clinical and commercial production.
To solve the troubles for enterprises, the entire CDMO industry will develop rapidly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
In recent years, they have become a hot spot in the research and development of global pharmaceutical companies, and are gradually applied to the research and development of new therapies in the fields of tumors, pain, and metabolic diseases
.
Compared with small molecule drugs, the number of peptide drugs that have been approved for marketing is relatively small, and the industry believes that the growth potential of this drug is huge
.
At present, Pfizer, Merck, Roche, Eli Lilly, Novartis, Sanofi, Bayer and other multinational pharmaceutical companies have increased their R&D investment in the field of peptide drug research, and actively deployed through mergers and acquisitions
.
In recent years, the effect of head companies has become prominent, including Lilly's dulaglutide, Novo Nordisk's semaglutide, and Takeda Pharmaceutical's leuprolide acetate, all of which are blockbuster varieties with annual sales of hundreds of millions of dollars
.
In China, with the rapid development of foreign peptide drug research and development and the rapid development of the peptide drug market, some local pharmaceutical companies have gradually joined the field, aiming at the blue ocean of the market
.
For example, Ambio Pharmaceuticals, Sino Biological, Nuotai Biological, Asymchem,
etc.
Recently, the deployment of peptide drugs by many pharmaceutical companies has also attracted the attention of the industry
.
For example, Yuekang Pharmaceutical told investors on the interactive platform on February 21 that the company's peptide drugs are currently in the preclinical research stage in China.
For the progress of the project, please pay attention to the follow-up project progress announcement and regular reports; January 28 In the research report, Nuotai Biological mentioned that the company currently has 4 peptide CDMO projects in the early stage in the process of cooperation promotion
.
If there are relevant major developments, the company will disclose it in relevant announcements and periodic reports in accordance with the requirements of the listing rules
.
In addition to the application in the field of medicine, the application of peptide drugs in other fields has also attracted the attention of investors
.
The secretary of the board of Hanyu Pharmaceutical recently replied to investors that the active ingredient polypeptide can be used in the development of drugs and skin care products
.
Among them, in terms of innovative peptide drugs, the future research and development directions include tumor/immune system, anti-virus, anti-infection, vaccine, central nervous system, metabolism and other emerging treatment and prevention fields
.
In terms of skin care products, Hanyu Original, a subsidiary of Hanyu Pharmaceutical, is mainly engaged in the wholesale and retail of peptide skin care products.
Online sales on e-commerce platforms
.
According to relevant statistics, the peptide drug market in 2020 has reached 28.
5 billion US dollars, and the market is developing rapidly.
The industry expects that the market value of peptide drugs will increase by 9% in the next five years
.
The growth space of the entire peptide drug market is huge
.
It is worth mentioning that in recent years, with the entry of a large number of domestic and foreign pharmaceutical companies, the competition on the track has become more intense
.
Statistics show that as of February 2021, there are about 80 approved peptide drugs in the world, and more than 400 peptide molecules are in preclinical research
.
It is foreseeable that the competition in this market will be more intense in the future, and companies with a preemptive layout and rich product lines are expected to benefit
.
The industry also pointed out that although the market prospect of peptide drugs is promising, the enterprises that deploy drugs will still face challenges such as production capacity resource constraints, imperfect process research and development capabilities, and single platform in the process of advancing drugs to clinical and commercial production.
To solve the troubles for enterprises, the entire CDMO industry will develop rapidly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
